21 completed, 11 recruiting, 11 unknown, 7 not yet recruiting. 55 Phase 2, 5 Phase 1, 5 Phase 3.
Follow Population Groups: new trials by email Literature Review of Population Groups trials Research Report on Population Groups
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease Simenafil Hydrochloride Tablets 2.5 mg, Simenafil Hydrochloride Tablets 5 mg, Simenafil Hydrochloride Tablets 10 mg - Alzheimer Disease | Phase 2 | Not yet recruiting | Vigonvita Life Sciences | 200 | 2026-11-01 | 2026-10-29 |
| Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma reduced dose group, Standard Dose Group, concurrent chemoradiotherapy - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Not yet recruiting | Fudan University | 269 | 2026-09-01 | 2026-08-27 |
| Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults VV119 2mg, VV119 4mg, VV119 6mg - Schizophrenia | Phase 2 | Not yet recruiting | Vigonvita Life Sciences | 500 | 2026-07-31 | 2026-07-15 |
| A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease H021 Enteric-coated Tablets Low-dose Group, H021 Enteric-coated Tablets High-dose Group, Placebo Group - Crohn's Disease | Phase 2 | Not yet recruiting | Jiangsu Carephar Pharmaceutical Co., Ltd. | 156 | 2026-07-12 | 2026-06-30 |
| SG301-SC Injection Safety Study in Subjects With Primary ITP Patients low dose group, high dose group, Placebo group - Primary Immune Thrombocytopenia | Phase 2 | Recruiting | Hangzhou Sumgen Biotech Co., Ltd. | 60 | 2026-06-11 | 2026-09-09 |
| A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders JL18008 20 μg/kg, Placebo (for 20 μg/kg Group), JL18008 40 μg/kg - HIV Infections | Phase 1 / Phase 2 | Recruiting | Jecho Biopharmaceuticals Co., Ltd. | 30 | 2026-05-26 | 2026-08-06 |
| A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression Placebo group, JS1-1-01 low-dose group, JS1-1-01 high-dose group - Depression | Phase 2 / Phase 3 | Not yet recruiting | Tasly Pharmaceutical Group Co., Ltd | 180 | 2026-04-30 | 2026-04-08 |
| Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU) Nafamostat Low-Dose Group, Nafamostat High-Dose Group - Continuous Renal Replacement Therapy (CRRT) | Phase 2 | Recruiting | Zhujiang Hospital | 92 | 2026-04-07 | 2026-11-18 |
| Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke. QHRD106 Injection (Low-dose group), QHRD106 Injection (Middle-dose group), QHRD106 Injection (High-dose group) - Acute Ischemic Stroke | Phase 2 | Recruiting | Changzhou Qianhong Bio-pharma Co., Ltd. | 320 | 2026-01-19 | 2026-02-09 |
| A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) Test drug CB03-154 5mg group, Test drug CB03-154 10mg group, Test drug CB03-154 15mg group - ALS (Amyotrophic Lateral Sclerosis) | Phase 2 / Phase 3 | Recruiting | Shanghai Zhimeng Biopharma, Inc. | 240 | 2025-10-30 | 2026-09-22 |
| Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis CM336 Injection(Low dose group), CM336 Injection(High dose group) - Primary Light-Chain Amyloidosis | Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 90 | 2025-07-25 | 2025-11-26 |
| Lemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients Lemborexant 5 mg, Control (placebo) group - Delirium - Postoperative, Cardiac Surgery | Phase 2 | Not yet recruiting | University of British Columbia | 60 | 2025-05-01 | 2025-04-23 |
| Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD LV232 40mg, LV232 60mg, Escitalopram - MDD | Phase 2 | Recruiting | Vigonvita Life Sciences | 400 | 2025-04-03 | 2026-10-20 |
| Evaluation of Postoperative Pain in Cases Undergoing Cataract Surgery Under Topical Versus General Anesthesia Topical Anaesthesia group, General Anaesthesia group - Topical Anaesthesia, General Anesthetic Drug Adverse Reaction | Phase 1 / Phase 2 | Active not recruiting | Alexandria University | 50 | 2025-04-02 | 2025-12-17 |
| A Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride in Gastroscopy/Colonoscopy ET-26HCl 0.6mg/kg group, ET-26HCl 0.8mg/kg group, Etomidate Injectable Product 0.3mg/kg group - Gastroscopy, Colonoscopy | Phase 2 | Completed | Ahon Pharmaceutical Co., Ltd. | 78 | 2024-11-15 | 2025-05-25 |
| The Androtriol Injection for the Treatment of Acute Ischemic Stroke Androtriol Injection (High-dose group), Androtriol Injection (Low-dose group), Hydroxypropyl-β-cyclodextrin injection - Acute Ischemic Stroke | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 300 | 2024-10-31 | 2024-11-07 |
| Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease Mepolizumab low dose group, Mepolizumab middle dose group, Mepolizumab high dose group - Coronary Artery Disease | Phase 2 | Recruiting | Xijing Hospital | 18 | 2024-10-16 | 2026-01-23 |
| SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies SAL-0951 tablets 4mg, SAL-0951 tablets 5mg - Anemia | Phase 2 | Recruiting | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 60 | 2024-09-14 | 2024-12-17 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy Test drug CB03-154 5mg group, Test drug CB03-154 10mg group, Test drug CB03-154 20mg group - Focal Epilepsy | Phase 2 | Recruiting | Shanghai Zhimeng Biopharma, Inc. | 180 | 2024-08-14 | 2026-09-22 |
| A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression Placebo group, JS1-1-01 low-dose group, JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules - Depression | Phase 2 | Completed | Tasly Pharmaceutical Group Co., Ltd | 267 | 2023-12-26 | 2025-11-19 |
Showing 20 of 55. Sign in to see all of them.
Ischemic Stroke (3) · Alzheimer Disease (2) · Cicatrix (2) · Crohn Disease (2) · Depression (2) · Diabetic Nephropathies (2) · Essential Hypertension (2) · Heart Failure (2) · Osteoarthritis, Knee (2) · Amyotrophic Lateral Sclerosis (1) · Anemia (1) · Anxiety, Separation (1) · Arrhythmias, Cardiac (1) · Breast Neoplasms (1) · COVID-19 (1)
Tasly Pharmaceutical Group Co., Ltd (6) · Vigonvita Life Sciences (3) · Changchun GeneScience Pharmaceutical Co., Ltd. (2) · Maternal and Child Health Hospital of Foshan (2) · Shanghai Zhimeng Biopharma, Inc. (2) · AIM Vaccine Co., Ltd. (1) · Aalborg University Hospital (1) · AbbVie (prior sponsor, Abbott) (1) · Ahon Pharmaceutical Co., Ltd. (1) · Alexandria University (1) · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (1) · Anterogen Co., Ltd. (1) · Assiut University (1) · Beijing Tiantan Hospital (1) · Boryung Pharmaceutical Co., Ltd (1)
China (33) · United States (4) · South Korea (3) · Egypt (2) · Japan (2) · Australia (1) · Canada (1) · Croatia (1) · Denmark (1) · Norway (1) · Romania (1) · Saudi Arabia (1) · Taiwan (1)
Xiaoping Luo (2) · Zhengping Liu, MD (2) · Brian H. Kushner, MD (1) · Byung-He Oh, Professor (1) · Chao Gao, M.D., Ph.D. (1) · Chunde Bao, M.D. & Ph.D. (1) · DS Kim (1) · Dae-Il Chang (1) · Dong-Soo Kim, Professor (1) · Fengcai Zhu (1) · Gang An (1) · Gi-Sik Kim, professor (1) · Hesheng He (1) · Hongmei Jing (1)
PMID 11642645, PMID 15050897, PMID 16204011, PMID 17075123, PMID 2156418, PMID 22203761, PMID 22233247, PMID 22455987, PMID 22659077, PMID 23108976, PMID 23257654, PMID 23633099, PMID 23932463, PMID 24722445, PMID 25416198, PMID 26153128, PMID 26403468, PMID 27104183, PMID 27310019, PMID 27552452, PMID 27845852, PMID 28291178, PMID 28756065, PMID 29417902, PMID 29499740, PMID 30138014, PMID 3028661, PMID 3068365, PMID 30774462, PMID 31651889, PMID 32278352, PMID 32436160, PMID 32586366, PMID 33420185, PMID 33773111, PMID 3479839, PMID 35871083, PMID 36329428, PMID 38169574, PMID 39899673, PMID 42861767, PMID 9060524